{"title": "Press Room", "author": null, "url": "https://www.news.sanofi.us/press-releases", "hostname": "sanofi.us", "description": null, "sitename": "news.sanofi.us", "date": "2023-08-24", "cleaned_text": "Skip to main content Welcome to Sanofi About us About us U.S. LEADERSHIP Our Stories Corporate Compliance Corporate Compliance California Compliance Law Shannon Kelley California Compliance Law - Sanofi Pasteur Compliance Program for Sanofi Pasteur Committed to Transparency Sanofi Websites in the U.S. Your Health Your Health Vaccines Science & Innovation Science & Innovation Clinical Trials INVESTIGATOR SPONSORED STUDIES (ISS) Products & Resources Products & Resources Prescription Products Vaccines Products Vaccines Products Yellow Fever Vaccine Information Generics Consumer Health (OTC) Products U.S. Patents Patient Support Services Resources for Healthcare Providers Colorado Disclosure Vermont Disclosure Our Responsibility Our Responsibility Corporate Social Responsibility Access to Healthcare Patient Advocacy at Sanofi in the U.S. Patient Advocacy at Sanofi in the U.S. Health Equity at Sanofi in the U.S. 2023 Health Equity Accelerator Awards: Application Guidelines 2022 Health Equity Accelerator Award Winners Health Equity Accelerator Awards Aim to Expand Solutions for Bigger Impact Patient Centered Healthcare Value Assessment Diversity, Equity & Inclusion Diversity, Equity & Inclusion A Million Conversations: Addressing Disparities in Healthcare Diversity in Clinical Trials Employee Resource Groups Supplier Diversity Contributions and Giving Contributions and Giving TORCH Awards Sponsorships Philanthropic Donations Healthcare Contributions Independent Medical Education (IME/CME) Grants Fellowships Rare Genetic Disease Fellowships Patient Assistance Foundations Pricing Principles Pricing Principles 2023 Pricing Principles Report Clear Rationale for Pricing Limited U.S. Price Increases Continued Transparency in the U.S. Prioritizing Patient Affordability Healthy Planet Careers Careers Benefits Diversity Postdoctoral Careers Physician Careers Students Veterans Investors Media WORLDWIDE PRESENCE Toggle navigation Home Press Releases Subscribe Social Media Media Contacts Press Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Category All Categories Corporate News Product News Vaccines News Uncategorized Keywords Go Advanced Search Search Search Headlines Only Category All Categories Corporate News Product News Vaccines News Uncategorized From To Asset Types Video Audio Photos Documents Events Standard Basic Search Aug 24, 2023 Beyfortus (nirsevimab-alip) recommended for routine use to protect infants against RSV disease in CDC Morbidity and Mortality Weekly Report The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season Aug 3, 2023 U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus (nirsevimab-alip) to protect infants against RSV disease Jul 25, 2023 Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact Jul 17, 2023 FDA approves Beyfortus (nirsevimab-alip) to protect infants against RSV disease Jun 25, 2023 ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing Show 5 10 25 50 100 per page \u00ab 1 2 3 4 5 6 7 8 9 ... 190 \u00bb "}